PRT382 demonstrated optimal enzymatic kinetics in vitro, producing an IC50 of 2.8 nM in filtration binding assays with recombinant human PRMT5/MEP50 and histone H2A as the protein substrate (Fig. 6c), and an IC50 of 27 nM in a reducing sDMA assay in the Granta-519 lymphoma cell line (Fig. 6d). The gene discussed is PRMT5; the disease is lymphoma.